le Roux C, et al. - This post-hoc analysis was performed to examine whether the efficacy and safety of liraglutide 3.0 mg differed between 2 subgroups (BMI 27 to <35 and BMI ≥ 35 kg/m²) in individuals without and with type 2 diabetes (T2D). The researchers found no differences in the treatment effects, or safety profile, of liraglutide 3.0 mg for individuals with BMI 27 to <35 or ≥35 kg/m². Thus, liraglutide 3.0 mg could be considered for individuals with a BMI of ≥35 as well as for those with a BMI of 27 to <35 kg/m².